
Short Title: GO46747
Enrollment Status: Recruiting
NCT #: NCT07541079
Specialty Area: Oncology
Condition Studied: Estrogen Receptor-Positive (ER+), HER2-Negative (HER2−) Early Breast Cancer
Age Groups: Adult; Older Adult
Phase: III
The purpose of this study is to determine whether switching to giredestrant provides a tolerable treatment option for patients with ER-positive, HER2-negative early breast cancer who are unable to tolerate aromatase inhibitor therapy while assessing patient-reported symptoms, quality of life, and treatment discontinuation.

Location: Renown Health, Office of Clinical Research
Address:
Complete Study Details: https://clinicaltrials.gov/study/NCT07541079
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.